When glucose is taken orally, insulin secretion is stimulated much more than it is when
glucose is infused intravenously so as to result in similar glucose concentrations. This effect …

Exenatide (synthetic exendin-4), glucagon-like peptide-1 (GLP-1), and GLP-1 analogues
have actions with the potential to significantly improve glycemic control in patients with …

Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2
diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative …

Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important
factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential …

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide-1 (GLP-1) are secreted from the intestinal K-and L-cells, respectively, but are …

Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent
insulinotropic and glucagonostatic actions, trophic effects on the pancreatic β-cells, and …

Ingestion of food results in the release of peptide hormones in the gut, termed incretins, that
regulate insulin in a glucose-dependent manner. 1 When blood glucose levels are high, the …

Abstract Glucagon-like peptide-1 (GLP-1) is an incretin hormone with antidiabetic action
through its ability to stimulate insulin secretion, increase beta cell neogenesis, inhibit beta …

Recent studies have indicated that GIP and GLP-1 are about as important as each other in
the incretin effect, being released rapidly after meals and being active already at fasting …

Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both
diabetologists and the pharmaceutical industry alike, as they may become established as …